(Q35589645)

9 August 2017

Cutting edge: Antimalarial drugs inhibit IFN-β production through blockade of cyclic GMP-AMP synthase-DNA interaction (English)

1 reference

9 August 2017

0 references

Jie An

1

1 reference

9 August 2017

Joshua J Woodward

2

1 reference

9 August 2017

Tomikazu Sasaki

3

1 reference

9 August 2017

Mark Minie

4

1 reference

9 August 2017

Keith B Elkon

5

1 reference

9 August 2017

language of work or name

English

0 references

publication date

27 March 2015

1 reference

9 August 2017

Journal of Immunology

1 reference

9 August 2017

194

1 reference

9 August 2017

9

1 reference

9 August 2017

4089-4093

1 reference

Type I IFN system in the development and manifestations of SLE.

9 August 2017

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

Type I interferonopathies: a novel set of inborn errors of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome autoantigen-associated RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

Trex1 prevents cell-intrinsic initiation of autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

TREX1 deficiency triggers cell-autonomous immunity in a cGAS-dependent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

21 January 2018

Immune sensing of DNA

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

CANDO and the infinite drug discovery frontier

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

UCSF Chimera--a visualization system for exploratory research and analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

Structural mechanism of cytosolic DNA sensing by cGAS

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

Cyclic GMP-AMP Synthase Is Activated by Double-Stranded DNA-Induced Oligomerization

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

New insights into mechanisms of therapeutic effects of antimalarial agents in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

Cree encephalitis is allelic with Aicardi-Goutiéres syndrome: implications for the pathogenesis of disorders of interferon alpha metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 cause Aicardi-Goutières syndrome at the AGS1 locus

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

Pharmacokinetics of quinacrine efflux from mouse brain via the P-glycoprotein efflux transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402793

21 January 2018

Identifiers

DOI

10.4049/JIMMUNOL.1402793

1 reference

9 August 2017

1 reference